Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis

Diabetes Technology and Therapeutics

Volumn 14, Issue 7, 2012, Pages 635-643

  Odawara, Masato ^a   Ohtani, Tetsuya ^b   Kadowaki, Takashi ^c  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Sanofi aventis KK ^*  (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE;

ADULT; AGED; ARTICLE; BASAL SUPPORTED ORAL THERAPY; BEDTIME DOSAGE; BODY MASS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG THERAPY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES;

EID: 84863809670     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0220     Document Type: Article

References (29)

1. Riddle MC, Rosenstock J, Gerich J: The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
2. Barnett A: Dosing of insulin glargine in the treatment of type 2 diabetes. Clin Ther 2007;29:987-999
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203
4. Japan Diabetes Society: Diabetes Therapeutic Guide. Tokyo: Bunkodo Co., Ltd., 2010
5. Kobayashi M, Yamazaki K, Kanatsuka A; Japanese Diabetes Clinical Data Management Study Group: Comparison between long-acting and biphasic insulin analogs in patients with type 2 diabetes: CoDiC-data analysis [in Japanese]. Shinyaku to Rinsho 2009;58:897-904
6. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-408
7. Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, Ilkova H, Ramachandran A, Aschner P; IDMPS Investigators: Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009;32:227-233.
8. Fukushima M, Suzuki H, Seino Y: Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004;66(Suppl 1):S37-S43.
9. Ohtani T, Ito T: Safety and effectiveness of BOT (Basal supported Oral Therapy) using insulin glargine in Japanese patients with type 2 diabetes-results from post-marketing surveillance of insulin glargine (ALOHA Study) [in Japanese]. Shinyaku to Rinsho 2011;60:458-475
10. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K: Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010;1: 212-228
11. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802.
12. Development Core Team: R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2011
13. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451.
14. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R: Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008;10:387-399.
15. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28: 254-259
16. Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, Lahdenperä S, Nijpels G, Vähä talo M: Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic atients individually and in groups. Diabetes Care 2007;30:1364-1369
17. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E: A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-742
18. Pan CY, Sinnassamy P, Chung KD, Kim KW: Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract 2007;76:111-118
19. Schreiber SA, Haak T: Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007;9:31-38
20. Mayfield JA, White RD: Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004;70:489-500
21. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371:1753-1760
22. Goto H, Hirose T, Shimizu T, Mita T, Igarashi Y, Fujitani Y, Tanaka Y, Watada H, Kawamori R: Effectiveness of combination therapy with a sulfonylurea and once-daily insulin glargine in Japanese type 2 diabetic patients- evaluation of the long-term (18 months) results of the combination therapy [in Japanese]. Tonyobyo 2007;50: 591-597
23. Ryan AS: Insulin resistance with aging: effects of diet and exercise. Sports Med 2000;30:327-346
24. Kobayashi M, Yamazaki K, Kanatsuka A; Japanese Diabetes Clinical Data Management Study Group: CoDiC-: surveillance of clinical management of diabetes in Japan (2nd report). Jpn J Diabetes Master Clinician 2007;5:401-406
25. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER; Action to Control Cardiovascular Risk in Diabetes Investigators: Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990
26. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
27. Fritsche A, Schweitzer MA, Haring HU: Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-959
28. ATLAS Study Group: Titration of insulin glargine in patients with type 2 diabetes mellitus in Asia: physician- versus patient- led? Rationale of the Asian Treat to Target Lantus Study (ATLAS). Diabetes Technol Ther 2011;13:67-72.
29. Kawamori R, Kaku K, Kasuga M, Kadowaki T, Kobayashi M, Satoh J, Tajima N, Haneda M, Shuto Y: Safety and effectiveness of biphasic insulin aspart 30 (BIAsp30) in patients with type 2 diabetes (T2D)-IMPROVE Study in Japan [in Japanese]. Jpn Pharmacol Ther 2009;37:233-241.